Open an account

Kairos Pharma

KAPA · NYSE American

$0.5837+$0.0136 (+2.39%)TodayMarket closed ·
Prev close $0.5701

About KAPA

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. The company is headquartered in Los Angeles, California and currently employs 1 full-time employees. The company went IPO on 2024-09-16. The firm is engaged in advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. Its therapy includes antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its portfolio consists of seven drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301 and 401 and therapeutic agents ENV 105 and 205. KROS 101 is a small molecule that targets the glucocorticoid-induced tumor necrosis factor ligand-related (GITR) ligand, a signal for T cell growth to remove a checkpoint barrier to fight a host of cancers. KROS 201 is a T cell therapy activated by dendritic cells to treat glioblastoma, a deadly and common brain cancer. ENV 105 drug seeks to address unmet medical needs in large markets of prostate and lung cancers.

Employees
3
Headquarters
Los Angeles, California
Listed
Sep 16, 2024
Sector
Health Care
Industry
Biotechnology
Website
kairospharma.com

KAPA key statistics

Market cap
1.98M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
990.15K
Volume
153.53K
Open price
$0.56
High today
$0.6029
Low today
$0.5302
52 Week high
$8.53
52 Week low
$0.5215

Kairos Pharma (KAPA) at a glance

Kairos Pharma (KAPA) last traded at $0.5837, with a market cap of 1.98M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.5302 and $0.6029. The current price is 10.1% above the day's low and 3.2% below its high.

Volume so far is 153.53K shares, below the average of 990.15K shares a day.

Over the past year Kairos Pharma has ranged from $0.5215 to $8.53, and now sits 1% of the way up that range.

Kairos Pharma met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$0.42 per share against an estimate of -$0.5712.

The average analyst price target is $49.98, 8462.6% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $49.98
Low
$14.14
Now
$0.5837
High
$88.20

KAPA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 26.5% on average.

  1. Q3 FY24: reported -$0.70 per share against an estimate of -$0.1428
  2. Q4 FY24: reported -$0.56 per share against an estimate of -$0.2499
  3. Q1 FY25: reported -$0.56 per share against an estimate of -$0.357
  4. Q2 FY25: reported -$0.56 per share against an estimate of -$0.3927
  5. Q3 FY25: reported -$0.49 per share against an estimate of -$0.476
  6. Q4 FY25: reported -$0.49 per share against an estimate of -$0.3808
  7. Q1 FY26: reported -$0.56 per share against an estimate of -$0.5355
  8. Q2 FY26: reported -$0.42 per share against an estimate of -$0.5712

KAPA news

  • Vandana Singh

    Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer

  • Press releaseBusiness Wire

    Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer

  • Press releaseBusiness Wire

    Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA

  • Press releaseBusiness Wire

    Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Rishabh Mishra

    Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Slip Ahead of Data-Heavy Week, Nvidia Earnings, and Jackson Hole—BABA, PMI, BIRK in Focus (UPDATED)

  • Press releaseBusiness Wire

    Kairos Pharma Announces 1-for-7 Reverse Stock Split

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

Similar companies

Companies in the same industry as Kairos Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.